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The human immunodeﬁciency virus (HIV), causing the ac-
quired immunodeﬁciency syndrome (AIDS), was ﬁrst re-
ported thirty years ago. The UNAIDS published the latest
statistics on the global HIV and AIDS epidemic in November
2010 and estimated that in 2009 there were 33.3 million
people living with HIV/AIDS worldwide (Worldwide HIV
and AIDS statistics, http://www.avert.org/worldstats.htm).
While the annual number of new HIV infections has steadily
declined, and the number of people receiving antiretroviral
therapy increased, the HIV pandemic has so far caused the
death of nearly 30 million people from AIDS-related causes.
The sub-Saharan African region carries the greatest burden
ofthispandemic,with22.5millionadultsandchildrenliving
with HIV/AIDS in 2009. In South Africa alone, there are an
estimated 5.6 million HIV-infected people, more than in any
other country, with almost one in three women aged 25–29,
and over a quarter of men aged 30–34, living with HIV (HIV
and AIDS in South Africa, http://www.avert.org/aidssouth-
africa.htm).
Tuberculosis (TB) is an important public health problem
representing the most frequent opportunistic infection in
HIV infected persons globally. In 1993, the World Health
Organization (WHO) declared TB a global public health
emergency, when an estimated 7-8 million cases and 1.3–1.6
million deaths occurred each year. Today, TB remains a lead-
ing cause of death in low- and middle-income countries, and
the latest WHO report on global TB control indicates that
there were an estimated 8.8 million incident cases and 1.4
milliondeathsfromTBin2010(http://www.who.int/tb/en/).
HIV infection is the greatest risk factor for acquiring
Mycobacterium tuberculosis (M.tb) infection and developing
TB. The devastating association between HIV and TB means
that up to 1.2 million (12–14%) of the new TB cases were
amongst HIV-infected people in 2010, and TB caused the
death of an estimated 0.35 million HIV-infected people. The
proportion of HIV-M.tb-coinfected persons is highest in
Africa, with the African Region accounting for overall 82%
of TB cases among people living with HIV.
The risk of TB is increased during all stages of HIV
infection from about 10% over a lifetime (in HIV-uninfected
individuals) to as high as 30% per annum in patients with
advanced HIV infection [1, 2]. These circumstances deﬁne
the analysis of the immune response to TB in the context
of HIV infection as a pressing research priority. This special
issue is therefore devoted to HIV-associated TB. It comprises
three review papers and six research papers.
The ﬁrst paper is a general overview of HIV-associated
TB and focuses on the intersecting HIV and TB epidemics
in countries with a high burden of both infections. Among
the many challenges, the authors discuss the diagnosis of
TB in HIV-infected patients, diﬃculties posed by antiretro-
viral drug interactions when treating HIV-M.tb-coinfected
patients, and the WHO-recommended interventions collec-
tively known as collaborative TB/HIV activities, such as HIV
testing in TB patients, integration of HIV and TB services,
provision of isoniazid preventive therapy (IPT), infection
control, minimizing airborne transmission, and managing
recurrent TB.2 Clinical and Developmental Immunology
The crucial question of when to initiate combined an-
tiretroviral treatment (cART) in relation to TB treatment,
balancing the increased risk of immune reconstitution in-
ﬂammatory syndrome (IRIS) associated with early cART
with the mortality associated with delaying HIV treatment,
is discussed in the second review paper. TB-associated IRIS
(TB-IRIS) is an important early complication of cART, re-
ﬂecting the fact that the immune responses to TB may con-
tribute to both protection and pathology. Two forms of TB-
IRIS are recognized: (1) paradoxical, that occurs in patients
who are established on TB treatment before cART, and man-
ifest with recurrent or new symptoms and clinical features
of TB after initiation of cART; (2) unmasking TB-IRIS, that
has been deﬁned in patients who are not receiving treatment
for TB when cART is started, but present with active TB
within 3 months of starting cART and show a heightened
intensity of clinical manifestations with a marked inﬂam-
matory component [3, 4]. The authors conclude that there
is compelling evidence that initiation of cART should not
be delayed in HIV/TB-coinfected individuals. The WHO
recommends the initiation of cART between 2 and 8 weeks
subsequent to the initiation of TB therapy in individuals
with CD4 counts <200/µL. Three publications (published
since this review paper) of clinical trials in patients with
HIV-associated TB [5–7] describe survival beneﬁts and in-
creased AIDS-free survival resulting from early cART initi-
ation after the start of TB therapy, particularly in persons
withfar-advancedimmunosuppression(CD4<50/µL),while
indicating that the risk of IRIS was higher with earlier than
withlatercARTinitiation.ThissurvivalbeneﬁtofearlycART
occurs despite the higher risk of IRIS in those started earlier
and in those with a CD4 count <50/µL, and despite the
fact that IRIS itself can be associated with mortality (case
fatality rate of 3.2% in a recent meta-analysis) [8]. Although
guidelines have been developed for resource-limited settings
(3),theneedtodetectandappropriatelytreatIRISinatimely
fashion outside of a controlled clinical study environment
remains a major challenge and requires further exploration.
The third paper discusses the concept of “latent tubercu-
losis infection” in HIV-infected individuals. Immunological
tests, such as tuberculin skin test (TST) and interferon-
gamma release assays (IGRAs) provide evidence of M.tb sen-
sitization in one-third of the global population. Thus, more
than two billion individuals are estimated to be latently in-
fectedwithM.tbandshownoclinicalsymptomsbutlivewith
the risk of subsequent progression to overt clinical disease,
particularly in the context of coinfection with HIV. The tra-
ditional paradigm that distinguishes latent M.tb infection
from active TB as two distinct compartmentalized states ap-
pears to be too simplistic. Recently, it has been suggested that
clinically deﬁned latent M.tb infection actually represents
oneextremeonaspectrum(ofimmuneresponses,mycobac-
terial metabolic activity, and bacillary numbers) that runs
from elimination of live bacilli to subclinical and clinical
symptomatic disease [9, 10]. The authors of this paper
propose that the impact of HIV infection on this spectrum
might be better conceptualized as a shift from controlled
infection towards poor immune control, higher mycobac-
terial metabolic activity, and greater organism load, with
subsequently increased risk of progression to active disease
and discuss the evidence for such a model as well as the
implications for interventions to control the HIV-associated
TB epidemic.
The six research papers and clinical studies in this special
issue follow the reviews in thematic order. Thus, the fourth
paper describes HIV-associated TB mortality and predictors
of death and survival in a tertiary care center in Brazil; the
ﬁfth and sixth describe the paradoxical consequences of dual
HIV and TB treatment (TB-IRIS) in Northern India and
Ugandaandtheirpredictors,followedbyapproachestodiag-
nosing M.tb infection and TB in HIV-infected people using
existing immunodiagnostic (IGRA) and proposed meth-
ods(antigen85reactivity).Theﬁnalpaperfocusesongenetic
factors (HLA-B∗57) and gender inﬂuencing the incidence of
TB in HIV-infected persons in Bangalore, India.
This issue shows that progress is being made in unrav-
elling the spectrum of protective and pathological immune
mechanisms in HIV and M.tb-coinfected persons, and the
approaches and consequences of their treatment. Indeed,
WHO in its 2011 report presents encouraging trends of
globally declining TB incidence rates at a time of broadening
therapeutic options, TB vaccine candidates in phases II and
III trials, and the development of fast and precise PCR-based
diagnostic tools. However, major obstacles such as poverty
and its consequences and availability of and access to health
care impact the HIV and M.tb pandemics, while at the same
time new attention is also needed on diabetes, cigarette
smoking, and air pollution as risk factors in TB endemic
areas. Bold goals such as “Zero Deaths” [11], increased dis-
ease-speciﬁc funding for treatment programs, development
of new diagnostics, vaccines, and biomedical and clinical
progress as presented here will be needed to sustain accom-
plishments and further decrease the HIV and TB impact on
global public health.
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